Tagged with

Biogaran Biogaran was an initiative from Servier in the mid 1990s before there was even a generic pharmaceutical market in France. Could you speak of your history and of the origins of Biogaran and the vision behind starting this company? Biogaran is in line with my previous experience as I was…

Janssen-Cilag France Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of the market not only in Europe but overall for the group? We are very proud of being the largest Johnson…

Endotis Pharma Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from near scratch in 2003 based on a specific project that was unsuccessful at the time but rejuvenated in 2005 with…

This interview was conducted with Jacques de Chilly and Theirry de Lumley of Aderly hereafter referred to as J.C. and T.L. respectively. Aderly was founded in 1974 in order to facilitate development in the Lyon region. How has the orientation of the group evolved over time and today, what are…

Actavis France Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an acquisition of Torlan Laboratoires. As the last actor to enter the market, what was the motivation to move into the…

CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in 1964. Its mission is to bring together the main stakeholders involved in the pharmaceutical industry; from pharmaceutical companies to wholesalers,…

Lyonbiopôle As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité?  The biggest differentiating point is that the clusters have been founded on government initiative to create competitive zones across multiple industries.…

Cegedim Deutschland GmbH You joined Cegedim in summer 2006 eleven months before its merger with Dendrite in 2007 that created the world leader in pharmaceutical CRM. How would you describe the integration process of both companies and what were the main synergies between Cegedim and Dendrite in the German context? Germany offered a…

Eisai France Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France going to bridge the gap between this blockbuster and the other developments that are coming down the pipeline? In regard…

Boehringer Ingelheim France There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these new facilities here at Paris Biopark. What does this express about the moves Boehringer Ingelheim is taking in France and…

Sanofi Aventis France As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health care industry since it seems that the industrial aspects have been overlooked in recent years. I would also like to…

Recordati Recordati was created in 1926, and the combined work of three generations turned the small laboratory not only into a local success story but also a broad European Group. Your grandfather Giovanni Recordati transformed an apothecary into a modern drug-based scientific business; your father Arrigo Recordati took the company towards…